THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen
MONACO — Canadians Alex Tessier, Sophie de Goede and Laetitia Royer have been named to World Rugby's Women’s 15s Dream Team of the Year. Canada sevens captain Olivia Apps, meanwhile, was selected to World Rugby's Women’s Sevens Dream Team. The women's 15s world all-star squad also featured six players from top-ranked England and three from No. 2 New Zealand. The other three came from the U.S., Ireland and France. Tessier was also a finalist for the World Rugby Women’s 15s Player of the Year award won by England fullback Ellie Kildunne. France's Pauline Bourdon Sansus and England's Alex Matthews were the other finalists. Tessier won her 50th cap in 2024 and, playing at inside centre alongside fly half Claire Gallagher, led the Canada women to a historic first-ever victory over New Zealand to win the 2024 Pacific Four Series in May. The 22-19 comeback victory lifted Canada into second place in the women’s world rankings, its highest position since November 2016. Tessier's strong kicking game was also key for Canada. The 31-year-old from Sainte-Clotilde-de-Horton, Que., scored 27 points in starting all six matches for Canada in 2024 to up her career total to 48 points (including five tries) in 54 appearances. Tessier plays professionally in England for the Exeter Chiefs. De Goede made the all-star team despite tearing her anterior cruciate ligament in training in June. A finalist for the Women's Player of the Year award in 2022, the Victoria back-rower plays in England for Saracens. Royer, from Loretteville, Que., is a second-row forward who plays in France for ASM Romagnat. Top-ranked South Africa dominated the men's 15s all-star squad with seven players represented. Ireland had four players with New Zealand three and Argentina one. --- World Rugby's 15s Dream Teams of the Year Women 1. Hope Rogers (U.S.); 2. Georgia Ponsonby (New Zealand); 3. Maud Muir (England); 4. Zoe Aldcroft (England); 5. Laetitia Royer (Canada) ; 6. Aoife Wafer (Ireland)' 7. Sophie de Goede (Canada) ; 8. Alex Matthews (England); 9. Pauline Bourdon Sansus (France); 10. Holly Aitchison (England); 11. Katelyn Vahaakolo (New Zealand); 12. Alex Tessier (Canada) ; 13. Sylvia Brunt (New Zealand); 14. Abby Dow (England); 15. Ellie Kildunne (England). Men 1. Ox Nche (South Africa); 2. Malcolm Marx (South Africa); 3. Tyrel Lomax (New Zealand); 4. Eben Etzebeth (South Africa); 5. Tadhg Beirne (Ireland); 6. Pablo Matera (Argentina); 7. Pieter-Steph du Toit (South Africa); 8. Caelan Doris (Ireland); 9. Jamison Gibson-Park (Ireland); 10. Damian McKenzie (New Zealand); 11. James Lowe (Ireland); 12. Damian de Allende (South Africa); 13. Jesse Kriel (South Africa); 14. Cheslin Kolbe (South Africa); 15. Will Jordan (New Zealand). World Rugby Sevens Dreams Team of the Year Women Olivia Apps (Canada) , Michaela Blyde (New Zealand), Kristi Kirshe (U.S.), Maddison Levi (Australia), Ilona Maher (U.S.), Jorja Miller (New Zealand), Séraphine Okemba (France). Men Selvyn Davids (South Africa), Antoine Dupont (France), Aaron Grandidier Nkanang (France), Terry Kennedy (Ireland), Nathan Lawson (Australia), Ponipate Loganimasi (Fiji), Matías Osadczuk (Argentina). This report by The Canadian Press was first published Nov. 27, 2024. The Canadian Press
Protests in Georgia Spark Investigation into Violent Power Takeover Attempt
The resolution ends a contentious chapter between the major U.S. bank and the electric vehicle leader JPMorgan Chase & Co. has agreed to drop its $162 million lawsuit against Tesla Inc. after a three-year legal dispute over stock warrants. Both companies announced the decision on Friday in a court filing in Manhattan, where they agreed to dismiss their claims against each other without the option to refile. Details of any settlement were not disclosed, and neither company responded to requests for comment. The lawsuit stemmed from a 2014 agreement in which Tesla sold stock warrants to JPMorgan. These warrants allowed the bank to buy Tesla shares at a specific price on a future date. JPMorgan alleged Tesla breached the contract in 2018 after a tweet from Tesla CEO Elon Musk caused the company’s stock to fluctuate significantly. In the tweet, Musk said he was considering taking Tesla private at $420 per share and claimed he had “funding secured.” He later abandoned the plan, causing further stock price volatility. JPMorgan adjusted the strike price of the warrants following the tweet and claimed Tesla owed payments based on these changes. Tesla countersued in 2023, accusing the bank of acting in bad faith to profit from the situation. The court filing on Friday came after a judge ruled against JPMorgan’s request to dismiss Tesla’s countersuit in September. The resolution ends a contentious chapter between the major U.S. bank and the electric vehicle leader. Save my name, email, and website in this browser for the next time I comment. Δ document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() );
Beep boop barf. On Tuesday, Kim Kardashian proved her thirst trap skills are getting rusty when she took to Instagram to post images from a sexy photo shoot with a new robot toy — a Tesla Optimus. In a grand display of clearly having her wires crossed on what human beings find appealing, the Skims founder donned lingerie and posed suggestively beside the gold robot, which sat in the driver’s seat of a matching gold Tesla Cybercab. The two Tesla products are still under development, but CEO Elon Musk has suggested that they could become available in the years ahead. Kardashian already owns a customized Tesla Cybertruck. In some of her photos, Kardashian squats beside the Cybercab, showing off her butt to the bot. In one memorable pic, she intertwines her fingers with the robot’s metallic ones. There are other photos in her Instagram slideshow, but honestly, we’re done describing them because they’re R2-D-too much. Many social media users felt the post was a downgrade for the reality TV star. “Sorry Kim, you’re not gonna normalise this weird behaviour for us we don’t want this!” one Instagram commenter said. “Kim this is a lot weird,” echoed another. “When you’ve gone through all of humanity’s dating pool...” a third commenter joked. Over on X, formerly Twitter, users were similarly grossed out. I speak on behalf of all the internet... We don't want to see this pic.twitter.com/DY1jIQ0lHe Kardashian has kept busy being a human advertisement for Musk recently. In September, she made headlines for customizing her Cybertruck , which was painted a specific shade of matte gray to match other cars in her fleet. And earlier this week, she posted video footage of herself playing around with a white Tesla Optimus. Other news outlets have retreated behind paywalls. At HuffPost, we believe journalism should be free for everyone. Would you help us provide essential information to our readers during this critical time? We can't do it without you. Can't afford to contribute? Support HuffPost by creating a free account and log in while you read. You've supported HuffPost before, and we'll be honest — we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you. Whether you give once or many more times, we appreciate your contribution to keeping our journalism free for all. You've supported HuffPost before, and we'll be honest — we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you. Whether you give just one more time or sign up again to contribute regularly, we appreciate you playing a part in keeping our journalism free for all. Already contributed? Log in to hide these messages. In one clip , Kardashian asks the bot: “Can you do this? I love you?” as she forms half of a heart shape with her hand. When the robot makes the other half, she gasps and says, “You know how to do that?” meet my new friend 🦾🤖 @Tesla pic.twitter.com/C34OvPA2dY But despite Kardashian’s apparent fondness for her new humanoid buddies, the consensus on her sexy robot photo shoot is that it megabytes. Related From Our Partner